eptinezumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
humanized origin	5386	1644539-04-7

Description:

Molecule

Description

Synonyms:

eptinezumab
eptinezumab-jjmr
vyepti
ALD403

Eptinezumab-jjmr is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Jan. 24, 2022	EMA	H. LUNDBECK A/S
Feb. 21, 2020	FDA	Lundbeck Seattle BioPharmaceuticals, Inc.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Throat irritation	112.48	41.05	34	765	37613	63450610
Drug ineffective	67.62	41.05	73	726	1044692	62443531
Headache	60.64	41.05	55	744	633186	62855037
Therapeutic response shortened	49.81	41.05	14	785	11874	63476349

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug ineffective	125.29	46.72	92	660	1080821	78662815
Throat irritation	110.42	46.72	32	720	40914	79702722
Headache	73.16	46.72	55	697	653717	79089919

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N02CD05	NERVOUS SYSTEM ANALGESICS ANTIMIGRAINE PREPARATIONS Calcitonin gene-related peptide (CGRP) antagonists
FDA EPC	N0000193952	Calcitonin Gene-related Peptide Antagonist
FDA MoA	N0000193953	Calcitonin Gene-related Peptide Antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Migraine	indication	37796009	DOID:6364
Prevention of migraine attacks	indication	408381007

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Calcitonin gene-related peptide 1	GPCR	P06881	CALCA_HUMAN	BINDING AGENT	Kd	10.82		DRUG LABEL	DRUG LABEL
Calcitonin gene-related peptide 2	GPCR	P10092	CALCB_HUMAN	BINDING AGENT	Kd	10.24		DRUG LABEL	DRUG LABEL

External reference:

ID	Source
8202AY8I7H	UNII
C4694272	UMLSCUI
CHEMBL3833320	ChEMBL_ID
DB14040	DRUGBANK_ID
CHEMBL2109621	ChEMBL_ID
10308	INN_ID
D11303	KEGG_DRUG
10694	IUPHAR_LIGAND_ID
018285	NDDF
870524004	SNOMEDCT_US
871787004	SNOMEDCT_US
4039215	VANDF
4039216	VANDF
2282660	RXNORM
331473	MMSL
38196	MMSL
38197	MMSL
d09520	MMSL
C000628361	MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Vyepti	HUMAN PRESCRIPTION DRUG LABEL	1	67386-130	INJECTION	100 mg	INTRAVENOUS	BLA	26 sections
Vyepti	HUMAN PRESCRIPTION DRUG LABEL	1	67386-130	INJECTION	100 mg	INTRAVENOUS	BLA	26 sections
Vyepti	HUMAN PRESCRIPTION DRUG LABEL	1	67386-130	INJECTION	100 mg	INTRAVENOUS	BLA	26 sections